Friday 6 November 2026
Export MTD’s income statement to Excel — free account
Mettler-Toledo International, Inc.
MTD Healthcare Diagnostics & Research
Mettler-Toledo International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, up 3.98% from fiscal 2024.
- Revenue
- +6.27%
- EPS
- +16.2%
- Free cash flow
- +33.0%
- Total debt
- −8.42%
Quarter to September 2026, against a year earlier
1,746.95
67.87
+4.04%
Follow MTD
Alert me
| Sep '26 From the 10-Q filed 6 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
32.66 | 28.68 | 29.50 | 33.01 |
+8 more quarters Free account |
P/S ratio |
7.18 | 6.22 | 6.26 | 7.14 | |
P/FCF ratio |
34.55 | 29.75 | 32.23 | 33.86 | |
P/Operating CF |
97.76 | 82.81 | 183.02 | 127.38 | |
P/B ratio |
388.41 | 2,004.62 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
7.65 | 6.72 | 6.79 | 7.65 | |
EV/EBITDA |
24.62 | 21.27 | 22.13 | 24.77 | |
EV/Operating CF |
32.65 | 28.47 | 30.80 | 32.25 | |
EV/FCF |
36.80 | 32.14 | 34.96 | 36.32 | |
Quick Ratio |
0.63 | 0.65 | 0.69 | 0.71 | |
Current Ratio |
1.10 | 1.12 | 1.20 | 1.14 | |
Net Debt/EBITDA |
0.00 | 5.93 | 8.36 | 5.54 | |
Debt/Assets |
54.76% | 57.53% | 60.74% | 57.97% | |
Debt/Equity |
26.06 | 164.70 | (53.21) | (91.05) | |
Asset Turnover |
1.16 | 1.17 | 1.18 | 1.16 | |
Operating CF/Net income |
1.25 | 1.33 | 0.83 | 0.79 | |
Capex/Depreciation |
0.00 | (0.85) | (0.53) | (1.27) | |
Interest Coverage |
0.00 | 18.23 | 13.32 | 19.75 | |
Research and Development Expense of Revenue |
4.90% | 5.16% | 5.41% | 4.66% | |
Selling, General and Administrative Expense of Revenue |
24.41% | 25.63% | 27.27% | 23.00% | |
Intangible Assets out of Total Assets |
0.27 | 0.27 | 0.28 | 0.27 | |
Share Based Compensation of Revenue |
0.54% | 0.52% | 0.58% | 0.57% | |
Graham Net Nets |
(0.07) | (0.09) | (0.09) | (0.08) | |
Graham Number |
63.63 | 25.27 | 0.00 | 0.00 | |
Earnings Yield |
3.06% | 3.49% | 3.39% | 3.03% | |
Free Cash Flow Yield |
2.89% | 3.36% | 3.10% | 2.95% | |
Revenue per Share |
54.81 | 51.05 | 46.69 | 54.81 | |
Operating CF per Share |
15.46 | 15.43 | 6.89 | 10.95 | |
Capex per Share |
0.00 | (1.38) | (0.86) | (2.01) | |
Free Cash Flow per Share |
15.46 | 14.05 | 6.03 | 8.93 | |
Cash per Share |
2.62 | 2.55 | 2.99 | 3.25 | |
Shareholders Equity per Share |
3.89 | 0.64 | (2.06) | (1.15) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.89 | 0.64 | (2.06) | (1.15) | |
Free Cash Flow |
308.57 | 282.62 | 122.38 | 184.08 | |
Working Capital |
125.87 | 146.89 | 223.55 | 164.55 | |
Capital Expenditures |
— | (27.79) | (17.41) | (41.50) | |
Net Current Asset Value |
(2,241.64) | (2,310.73) | (2,378.89) | (2,373.61) | |
EV/EBIT |
27.37 | 23.65 | 24.66 | 27.55 | |
Capex to Sales |
0.00 | 0.03 | 0.02 | 0.04 | |
Price to Operating Income |
25.69 | 21.89 | 22.73 | 25.69 | |
| Other line items | |||||
Average Receivables |
710.23 | 706.54 | 673.30 | 732.68 | |
Average Payables |
254.27 | 222.99 | 215.07 | 241.24 | |
Average Inventory |
420.73 | 399.82 | 381.81 | 364.75 | |
Average Assets |
3,608.47 | 3,535.70 | 3,451.80 | 3,476.32 | |
Average Common Equity |
(85.77) | (122.98) | (111.93) | (75.26) |
Columns are period end dates · fundamentals updated 6 Nov 2026